Combined Treatment of an Amyotrophic Lateral Sclerosis Rat Model with Recombinant GOT1 and Oxaloacetic Acid: A Novel Neuroprotective Treatment

Neurodegenerative Diseases

Volumn 15, Issue 4, 2015, Pages 233-242

  Ruban, Angela ^a   Cohen Kashi Malina, Katayun ^a   Cooper, Itzik ^b   Graubardt, Nadine ^a   Babakin, Leonid ^a   Jona, Ghil ^a   Teichberg, Vivian I ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Blood glutamate scavenger; Excitotoxicity; Glutamate; Neuroprotection; Sporadic amyotrophic lateral sclerosis

Indexed keywords

GLUTAMIC ACID; NEUROPROTECTIVE AGENT; OXALOACETIC ACID; RECOMBINANT GLUTAMATE OXALOACETATE TRANSAMINASE; UNCLASSIFIED DRUG; ASPARTATE AMINOTRANSFERASE; RECOMBINANT PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANESTHESIA LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORNEA REFLEX; DRUG HALF LIFE; MOTONEURON; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; ROTAROD TEST; TREATMENT OUTCOME; ANIMAL; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; KAPLAN MEIER METHOD; MALE; MOTOR ACTIVITY; PATHOLOGY; SPINAL CORD; WISTAR RAT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ASPARTATE AMINOTRANSFERASES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; KAPLAN-MEIER ESTIMATE; MALE; MOTOR ACTIVITY; MOTOR NEURONS; NEUROPROTECTIVE AGENTS; OXALOACETIC ACID; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; ROTAROD PERFORMANCE TEST; SPINAL CORD;

EID: 84939569665     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000382034     Document Type: Article

References (39)

1. Cleveland DW: From Charcot to SOD1: Mechanisms of selective motor neuron death in ALS. Neuron 1999; 24: 515-520.
2. Kretschmer BD, Kratzer U, Schmidt WJ: Riluzole, a glutamate release inhibitor, and motor behavior. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 181-190.
3. Miller RG, Mitchell JD, Moore DH: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012; 3:CD001447.
4. Shaw PJ, Forrest V, Ince PG, Richardson JP, Wastell HJ: CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995; 4: 209-216.
5. Sun H, Kawahara Y, Ito K, Kanazawa I, Kwak S: Slow and selective death of spinal motor neurons in vivo by intrathecal infusion of kainic acid: implications for AMPA receptormediated excitotoxicity in ALS. J Neurochem 2006; 98: 782-791.
6. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H: Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 2005; 25: 7101-7110.
7. de Groot JF, Piao Y, Lu L, Fuller GN, Yung WK: Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol 2008; 88: 121-133.
8. Eyupoglu IY, Hahnen E, Heckel A, Siebzehnrubl FA, Buslei R, Fahlbusch R, Blumcke I: Malignant glioma-induced neuronal cell death in an organotypic glioma invasion model. Technical note. J Neurosurg 2005; 102: 738-744.
9. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H: Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 2007; 67: 9463-9471.
10. Ruban A, Berkutzki T, Cooper I, Mohar B, Teichberg VI: Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas. Invest New Drugs 2012; 30: 2226-2235.
11. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M: Glutamate release promotes growth of malignant gliomas. Nat Med 2001; 7: 1010-1015.
12. Campos F, Perez-Mato M, Agulla J, Blanco M, Barral D, Almeida A, Brea D, Waeber C, Castillo J, Ramos-Cabrer P: Glutamate excitoxicity is the key molecular mechanism which is influenced by body temperature during the acute phase of brain stroke. PLoS One 2012; 7:e44191.
13. Campos F, Sobrino T, Ramos-Cabrer P, Castillo J: Oxaloacetate: a novel neuroprotective for acute ischemic stroke. Int J Biochem Cell Biol 2012; 44: 262-265.
14. Castillo J, Davalos A, Noya M: Progression of ischaemic stroke and excitotoxic amino acids. Lancet 1997; 349: 79-83.
15. Guyot LL, Diaz FG, O'Regan MH, McLeod S, Park H, Phillis JW: Real-time measurement of glutamate release from the ischemic penumbra of the rat cerebral cortex using a focal middle cerebral artery occlusion model. Neurosci Lett 2001; 299: 37-40.
16. Perez-Mato M, Ramos-Cabrer P, Sobrino T, Blanco M, Ruban A, Mirelman D, Menendez P, Castillo J, Campos F: Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia. Cell Death Dis 2014; 5:e992.
17. Baker AJ, Moulton RJ, MacMillan VH, Shedden PM: Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans. J Neurosurg 1993; 79: 369-372.
18. Feng JF, Gurkoff GG, Van KC, Song M, Lowe DA, Zhou J, Lyeth BG: Naag peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia. Brain Res 2012; 1469: 144-152.
19. Koura SS, Doppenberg EM, Marmarou A, Choi S, Young HF, Bullock R: Relationship between excitatory amino acid release and outcome after severe human head injury. Acta Neurochir Suppl 1998; 71: 244-246.
20. Richards DA, Tolias CM, Sgouros S, Bowery NG: Extracellular glutamine to glutamate ratio may predict outcome in the injured brain: a clinical microdialysis study in children. Pharmacol Res 2003; 48: 101-109.
21. Zauner A, Bullock R, Kuta AJ, Woodward J, Young HF: Glutamate release and cerebral blood flow after severe human head injury. Acta Neurochir Suppl 1996; 67: 40-44.
22. Spreux-Varoquaux O, Bensimon G, Lacomblez L, Salachas F, Pradat PF, Le Forestier N, Marouan A, Dib M, Meininger V: Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 2002; 193: 73-78.
23. Andreadou E, Kapaki E, Kokotis P, Paraskevas GP, Katsaros N, Libitaki G, Petropoulou O, Zis V, Sfagos C, Vassilopoulos D: Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis. In Vivo 2008; 22: 137-141.
24. Rothstein JD, Martin LJ, Kuncl RW: Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992; 326: 1464-1468.
25. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW: Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38: 73-84.
26. Heath PR, Shaw PJ: Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 2002; 26: 438-458.
27. Ikonomidou C, Turski L: Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 2002; 1: 383-386.
28. Muir KW: Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006; 6: 53-60.
29. Ruban A, Mohar B, Jona G, Teichberg VI: Blood glutamate scavenging as a novel neuroprotective treatment for paraoxon intoxication. J Cereb Blood Flow Metab 2014; 34: 221-227.
30. Zlotnik A, Gurevich B, Tkachov S, Maoz I, Shapira Y, Teichberg VI: Brain neuroprotection by scavenging blood glutamate. Exp Neurol 2007; 203: 213-220.
31. Gottlieb M, Wang Y, Teichberg VI: Bloodmediated scavenging of cerebrospinal fluid glutamate. J Neurochem 2003; 87: 119-126.
32. Uchihara T: Silver diagnosis in neuropathology: principles, practice and revised interpretation. Acta Neuropathol 2007; 113: 483-499.
33. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW: Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998; 281: 1851-1854.
34. Trotti D, Rolfs A, Danbolt NC, Brown RH Jr, Hediger MA: SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 1999; 2: 848.
35. Park JH, Hong YH, Kim HJ, Kim SM, Kim MJ, Park KS, Sung JJ, Lee KW: Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse model. Neurosci Lett 2007; 413: 265-269.
36. Zlotnik A, Gurevich B, Cherniavsky E, Tkachov S, Matuzani-Ruban A, Leon A, Shapira Y, Teichberg VI: The contribution of the blood glutamate scavenging activity of pyruvate to its neuroprotective properties in a rat model of closed head injury. Neurochem Res 2008; 33: 1044-1050.
37. Boyko M, Zlotnik A, Gruenbaum BF, Gruenbaum SE, Ohayon S, Kuts R, Melamed I, Regev A, Shapira Y, Teichberg VI: Pyruvate's blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms in a rat model of stroke. Eur J Neurosci 2011; 34: 1432-1441.
38. Campos F, Sobrino T, Ramos-Cabrer P, Argibay B, Agulla J, Perez-Mato M, Rodriguez-Gonzalez R, Brea D, Castillo J: Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab 2011; 31: 1378-1386.
39. Tsai PJ, Huang PC: Circadian variations in plasma and erythrocyte glutamate concentrations in adult men consuming a diet with and without added monosodium glutamate. J Nutr 2000; 130: 1002S-1004S.